Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018102890) VISUALIZATION CONSTRUCTS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/102890 International Application No.: PCT/AU2017/051365
Publication Date: 14.06.2018 International Filing Date: 11.12.2017
IPC:
A61K 38/14 (2006.01) ,A61K 38/12 (2006.01) ,A61K 47/50 (2017.01) ,A61K 47/60 (2017.01) ,A61K 49/00 (2006.01) ,C07K 1/04 (2006.01) ,C07K 1/13 (2006.01) ,C07K 9/00 (2006.01) ,G01N 21/64 (2006.01) ,G01N 33/68 (2006.01) ,A61P 31/04 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
14
Peptides containing saccharide radicals; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12
Cyclic peptides
[IPC code unknown for A61K 47/50][IPC code unknown for A61K 47/60]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49
Preparations for testing in vivo
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
1
General processes for the preparation of peptides
04
on carriers
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
1
General processes for the preparation of peptides
13
Labelling of peptides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
9
Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
21
Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible, or ultra-violet light
62
Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
63
optically excited
64
Fluorescence; Phosphorescence
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04
Antibacterial agents
Applicants:
THE UNIVERSITY OF QUEENSLAND [AU/AU]; - St Lucia, Queensland 4072, AU
Inventors:
BLASKOVICH, Mark; AU
Agent:
SPRUSON & FERGUSON; GPO Box 3898 Sydney, NSW 2001, AU
Priority Data:
201690510109.12.2016AU
Title (EN) VISUALIZATION CONSTRUCTS
(FR) CONSTRUCTIONS DE VISUALISATION
Abstract:
(EN) A visualization construct comprising: (i) an optionally derivatized glycopeptide antibiotic; (ii) a visualization component; and (iii) a first linker connecting (i) and (ii) is provided. The visualization component may be a fluorescent component, a quantum dot, an MRI visualization component, a PET or SPECT visualization component, an MPI visualization component, or a radiographic visualization component. The glycopeptide antibiotic may be vancomycin, teicoplanin, oritavancin; telavancin, chloroeremomycin, or balhimycin. The first linker may comprises a polyethylene glycol (PEG) moiety, or a linear carbon chain of greater than four carbons. Also provided are associated methods of producing and using related compounds, adducts, and constructs, such as methods of visualizing microorganisms.
(FR) L'invention concerne une construction de visualisation comprenant : (i) un antibiotique glycopeptidique éventuellement dérivé; (ii) un composant de visualisation; et (iii) un premier lieur liant (i) et (ii). Le composant de visualisation peut être un composant fluorescent, un point quantique, un composant de visualisation IRM, un composant de visualisation PET ou SPECT, un composant de visualisation MPI, ou un composant de visualisation radiographique. L'antibiotique glycopeptidique peut être la vancomycine, la téicoplanine, l'oritavancine, la télavancine, la chloroérémomycine ou la balhimycine. Le premier lieur peut comprendre une fraction polyéthylène glycol (PEG), ou une chaîne carbonée linéaire de plus de quatre carbones. L'invention concerne également des procédés associés de production et d'utilisation de composés, d'adduits et de constructions connexes, tels que des procédés de visualisation de micro-organismes.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)